Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01646125
First received: June 26, 2012
Last updated: November 3, 2014
Last verified: November 2014
  Purpose

The purpose of this study is to determine if AUY922 has superior efficacy when compared to chemotherapy agents docetaxel or pemetrexed in patients whose tumor have EGFR mutations.


Condition Intervention Phase
Advanced Non Small Cell Lung Cancer (NSCLC)
Drug: AUY922
Drug: Docetaxel
Drug: Pemetrexed
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter, Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Who Have Progressed on Prior EGFR TKI Treatment

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Progression Free Survival (PFS) [ Time Frame: up to 12 months ] [ Designated as safety issue: No ]
    To compare PFS between the treatment of AUY922 to comparators Pemetrexed or Docetaxel. PFS will be based on local investigator assessment per RECIST 1.1


Secondary Outcome Measures:
  • Overall Survival (OS) [ Time Frame: from randomization until death up to death ] [ Designated as safety issue: No ]
    OS is defined as the time from the date of randomization to date of death due to any cause. If a death has not been observed by the date of analysis cutoff, then OS will be censored at the last known date patient was alive.

  • Overall Response Rate (ORR) [ Time Frame: baseline, until disease progression up to 24 months ] [ Designated as safety issue: No ]
    ORR will be compared between treatment arms. The ORR will be based on local investigator assessment per RECIST 1.1

  • Disease Control Rate (DCR) [ Time Frame: baseline, until disease progression up to 24 months ] [ Designated as safety issue: No ]
    Duration of DCR will be compared between treatment arms. The duration of DCR will be based on local investigator assessment per RECIST 1.1

  • Time to Response (TRR) [ Time Frame: baseline, until disease progression up to 24 months ] [ Designated as safety issue: No ]
    TTR will be compared between treatment arms. The TTR will be based on local investigator assessment per RECIST 1.1

  • Duration of Response (DOR) [ Time Frame: baseline, until disease progression up to 24 months ] [ Designated as safety issue: No ]
    The DOR will be compared between treatment arms. The DOR will be based on local investigator assessment per RECIST 1.1

  • Rate of Adverse Events (AEs) [ Time Frame: baseline, until disease progression up to 24 months ] [ Designated as safety issue: Yes ]
    To evaluate safety and tolerability of AUY922 compared to chemotherapy agents pemetrexed or docetaxel.

  • Rate of serious Aadverse events (SAEs) [ Time Frame: baseline, until disease progression up to 24 months ] [ Designated as safety issue: Yes ]
    To evaluate safety and tolerability of AUY922 compared to chemotherapy agents pemetrexed or docetaxel.

  • Change in laboratory paramenters [ Time Frame: baseline, until disease progression up to 24 months ] [ Designated as safety issue: Yes ]
    Changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), Dose interruptions, reductions and dose intensity.

  • Time to Progression (TTP) [ Time Frame: baseline, until disease progression up to 24 months ] [ Designated as safety issue: No ]
    TTP will be compared between treatment arms. The TTP will be based on local investigator assessment per RECIST 1.1


Enrollment: 55
Study Start Date: November 2012
Estimated Study Completion Date: October 2015
Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AUY922 arm
AUY922 will be administered weekly
Drug: AUY922
AUY922 will be given i.v. once weekly at 70 mg/m2 until disease progression, death or any other reason for discontinuation from study treatment
Active Comparator: chemotherapy arm
docetaxel or pemetrexed will be given once every three weeks
Drug: Docetaxel
Docetaxel will be given i.v. once every 3 weeks at 75 mg/m2 until progression or unacceptable toxicity
Other Name: TAXOTERE
Drug: Pemetrexed
Pemetrexed will be given once every 3 weeks at 500 mg/m2 until progression or unacceptable toxicity
Other Name: ALIMTA

Detailed Description:

The primary purpose of this study is to compare the efficacy of AUY922, when administered i.v. on a once-weekly schedule at 70 mg/m2, versus docetaxel or pemetrexed in adult patients with advanced NSCLC, whose tumors harbor EGFR activating mutations, and have developed resistance to EGFR TKI.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with histologically or cytologically documented, locally advanced (stage IIIB who are not amenable to combined modality treatment) or recurrent or metastatic (Stage IV) non-small cell lung cancer.
  2. Patients must have EGFR gene mutation in their tumors. This can be source - documented by one of the following:

    • Provide a pathology report that indicates the patient's tumor had EGFR activating mutation in the past.

    Or:

    • Perform testing (local or central) in an archival tumor or a fresh baseline biopsy tumor tissue to show the presence of EGFR activating mutation.

  3. Patients must have documented clinical benefit (CR, PR, or patients with SD for 6 months or greater) on prior EGFR TKI (e.g. erlotinib or gefitinib) followed by documented progression according to RECIST.
  4. Patients must have received prior platinum containing treatment.
  5. WHO performance status of 0-1

Exclusion Criteria:

  1. Patients who have received more than two prior lines of antineoplastic therapy for advanced disease. Chemotherapy administered as neoadjuvant or adjuvant treatment more than six months prior to study enrollment is not considered a prior line of therapy for purposes of this study.
  2. Evidence of spinal cord compression or current evidence of CNS metastases. Screening CT/MRI of the brain is mandatory. Note: Patients who have been treated for CNS metastases by radiation or gamma knife surgery, who been stable for at least 2 months and have discontinued high dose corticosteroids will be eligible for protocol participation
  3. Prior treatment with an HSP90 inhibitor

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01646125

  Hide Study Locations
Locations
United States, California
Cedars Sinai Medical Center Dept.of Cedars-Sinai Med. Ctr.
Los Angeles, California, United States, 90048
United States, Maryland
Associates in Oncology/Hematology, P.C. SC
Rockville, Maryland, United States, 20850
United States, Wisconsin
University of Wisconsin / Paul P. Carbone Comp Cancer Center Univ Wisc 5
Madison, Wisconsin, United States, 53792-6164
France
Novartis Investigative Site
Creteil, France, 94000
Novartis Investigative Site
Marseille cedex 20, France, 13915
Novartis Investigative Site
Villejuif Cedex, France, 94805
Hong Kong
Novartis Investigative Site
Hong Kong, Hong Kong
Italy
Novartis Investigative Site
Monza, MB, Italy, 20900
Novartis Investigative Site
Milano, MI, Italy, 20133
Novartis Investigative Site
Parma, PR, Italy, 43100
Novartis Investigative Site
Orbassano, TO, Italy, 10043
Japan
Novartis Investigative Site
Koto, Tokyo, Japan, 135-8550
Korea, Republic of
Novartis Investigative Site
Seoul, Korea, Korea, Republic of, 135-710
Novartis Investigative Site
Seoul, Korea, Korea, Republic of, 120-752
Novartis Investigative Site
Seoul, Korea, Republic of, 738-736
Novartis Investigative Site
Seoul, Korea, Republic of, 137-701
Netherlands
Novartis Investigative Site
Amsterdam, Netherlands, 1081 HV
Novartis Investigative Site
Groningen, Netherlands, 9713 GZ
Norway
Novartis Investigative Site
Bergen, Norway, -N5021
Novartis Investigative Site
Oslo, Norway, NO-0424
Poland
Novartis Investigative Site
Gdansk, Poland, 80-952
Novartis Investigative Site
Warszawa, Poland, 02-781
Spain
Novartis Investigative Site
Barcelona, Catalunya, Spain, 08035
Novartis Investigative Site
Madrid, Spain, 28034
Taiwan
Novartis Investigative Site
Kuei-Shan Chiang, Taoyuan/ Taiwan ROC, Taiwan, 33305
Novartis Investigative Site
Taichung, Taiwan, 407
Novartis Investigative Site
Taipei, Taiwan, 10048
United Kingdom
Novartis Investigative Site
Maidstone, Kent, United Kingdom, M16 9QQ
Novartis Investigative Site
Leicester, United Kingdom, LE1 5WW
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided

Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT01646125     History of Changes
Other Study ID Numbers: CAUY922A2207, 2012-001050-25
Study First Received: June 26, 2012
Last Updated: November 3, 2014
Health Authority: United States: Food and Drug Administration
Australia: National Health and Medical Research Council
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Hong Kong: Department of Health
Norway: Norwegian Medicines Agency
Italy: National Monitoring Centre for Clinical Trials - Ministry of Health
Netherlands: Dutch Health Care Inspectorate
Netherlands: Medical Ethics Review Committee (METC)
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Spain: Spanish Agency of Medicines
South Korea: Korea Food and Drug Administration (KFDA)
Singapore: Clinical Trials & Epidemiology Research Unit (CTERU)
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Korea: Food and Drug Administration

Keywords provided by Novartis:
HSP90, AUY922, Pemetrexed, Docetaxel, EGFR TKI, EGFR mutations, NSCLC, non small cell lung cancer

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Docetaxel
Pemetrexed
Antimetabolites
Antimetabolites, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators

ClinicalTrials.gov processed this record on November 20, 2014